Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Main Article Content
Keywords
Alopecia areta, hair regrowth, Baricitinib, SALT Score
Abstract
Background Achievement of full scalp hair regrowth is an important outcome for patients with severe AA. Baricitinib is a selective JAK inhibitor that is approved in adults to treat severe AA and has now been studied in 257 adolescents (ages 12 to <18 years). In both populations, significant scalp hair regrowth (SALT score <20) was achieved in clinical trials. This analysis evaluates complete response thresholds of SALT score <10 and <5 among SALT score <20 responders, through Weeks (Wk) 36 and 52 in adolescent and adult populations, respectively.
Methods Among BRAVE-AA1/2 (NCT03570749, NCT03899259) and BRAVE-AA-PEDS (NCT05723198) trials, baricitinib 4mg and 2mg responders (SALT score ≤20) were evaluated for achievement of SALT score ≤10 or ≤5 at Wk4, 8, 12, 16, 24, 36, and 52*.
Results Among those patients treated with baricitinib 4mg, the proportion of adult responders who achieved SALT score <10 at Wk36 and Wk52 was 74.6% (150/201) and 75.0% (171/228); and the proportion in adolescents at Wk36 was 86.1% (31/36). Among those patients treated with baricitinib 4mg, the proportion of adults who achieved SALT score <5 at Wk36 and Wk52 was 55.2% (111/201) and 62.7% (143/228); and the proportion in adolescents at Wk36 was 61.1% (22/36). Some patients achieved these responses as early as Wk8 in both adult and adolescent populations.
Among those patients treated with baricitinib 2mg, the proportion of adults who achieved SALT score <10 at W36 and W52 was 62.2% (51/82) and 71.0% (66/93); and the proportion in adolescents at W36 was 78.3% (18/23). Among those patients treated with baricitinib 2mg, the proportion of adults who achieved a SALT score <5 at W36 and W52 was 42.7% (35/82) and 47.3% (44/93); and the proportion in adolescents at W36 was 60.9% (14/23). Some patients achieved these responses as early as W8 in both adult and adolescent populations.
Conclusion Baricitinib treated adult and adolescent patients who were responders (SALT score ≤20) had increasing depth of response over time with continued therapy, and the majority achieved full scalp hair regrowth.
Footnote *Week 52 data is not yet available for the BRAVE-AA-PEDS trial.
References
2. Passeron T, et al. Oral presentation at: AAD 2025.
3. King B, et al. N Engl J Med. 2022;386:1687-1699.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.